Inhibitory effects of sepiapterin on vascular endothelial growth factor-a-induced proliferation and adhesion in human umbilical vein endothelial cells

被引:0
作者
Soo Hyeon Kim
Young-Rak Cho
Myoung-Dong Kim
Hyun Ju Kim
Shin Wook Choi
Dong-Wan Seo
机构
[1] Kangwon National University,Department of Molecular Bioscience, Institute of Bioscience and Biotechnology, College of Biomedical Science
[2] Kangwon National University,Department of Food Science and Biotechnology, School of Biotechnology and Bioengineering
[3] Radiant Research Institute,Department of Molecular Bioscience, College of Biomedical Science
[4] Radiant Inc.,undefined
[5] Kangwon National University,undefined
[6] Radiant Inc.,undefined
来源
Archives of Pharmacal Research | 2011年 / 34卷
关键词
Tetrahydrobiopterin; Sepiapterin; Angiogenesis; Vascular endothelial growth factor-A; Endothelial cells;
D O I
暂无
中图分类号
学科分类号
摘要
Tetrahydrobiopterin (BH4) has been known to be an essential cofactor for the activities of nitric oxide (NO) synthase and aromatic amino acid hydroxylases, which are involved in physiological and pathological processes. In the present study, we report that sepiapterin, the more stable form of BH4 precursor, modulates vascular endothelial growth factor-A (VEGF-A)-induced cell proliferation and adhesion in human umbilical vein endothelial cells (HUVECs). The antiproliferative activity of sepiapterin in VEGF-A-treated HUVECs is associated with inhibition of the expression of cyclin-dependent kinases (Cdks) such as Cdk4 and Cdk2. Pretreatment with NO synthase inhibitor does not abrogate the ability of sepiapterin to inhibit VEGF-A-induced cell proliferation and adhesion, indicating that the suppressive effects of sepiapterin on VEGF-Ainduced responses are mediated by NO-independent mechanism. Finally, we show that sepiapterin modulates VEGF-A-induced cell proliferation and adhesion through down-regulation of VEGF receptor-2 downstream signaling pathways. Taken together, these findings represent a novel function of sepiapterin in the regulation of angiogenesis, supporting further development and evaluation of sepiapterin as an antiangiogenic agent.
引用
收藏
页码:1571 / 1577
页数:6
相关论文
共 151 条
[1]  
Alper O.(2001)Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells J. Natl. Cancer Inst. 93 1375-1384
[2]  
Bergmann-Leitner E. S.(2002)Metalloproteinase inhibitors: biological actions and therapeutic opportunities J. Cell Sci. 115 3719-3727
[3]  
Bennett T. A.(2010)Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion Semin. Cancer Biol. 20 161-168
[4]  
Hacker N. F.(2010)The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity Biochim. Biophys. Acta 1803 55-71
[5]  
Stromberg K.(2000)Angiogenesis in cancer and other diseases Nature 407 249-257
[6]  
Stetler-Stevenson W. G.(2010)Roles of tetrahydrobiopterin in promoting tumor angiogenesis Am. J. Pathol. 177 2671-2680
[7]  
Baker A. H.(2011)Sepiapterin inhibits cell proliferation and migration of ovarian cancer cells via down-regulation of p70 Oncol. Rep. 26 861-867
[8]  
Edwards D. R.(2006)-dependent VEGFR-2 expression Nature 441 444-450
[9]  
Murphy G.(2003)New signals from the invasive front Nat. Med. 9 669-676
[10]  
Bourboulia D.(2006)The biology of VEGF and its receptors Annu. Rev. Med. 57 1-18